A morphometric signature to identify ductal carcinoma in situ with a low risk of progression

A morphometric signature to identify ductal carcinoma in situ with a low risk of progression

Abstract Ductal carcinoma in situ (DCIS) may progress to ipsilateral invasive breast cancer (iIBC), but often never will. Because DCIS is treated as early breast cancer, many women with harmless DCIS face overtreatment. To identify features associated with progression, we developed an artificial int...

Full description

Saved in:
Bibliographic Details
Main Authors: Marcelo Sobral-Leite, Simon P. Castillo, Shiva Vonk, Hendrik A. Messal, Xenia Melillo, Noomie Lam, Brandi de Bruijn, Yeman B. Hagos, Myrna van den Bos, Joyce Sanders, Mathilde Almekinders, Lindy L. Visser, Emma J. Groen, Petra Kristel, Caner Ercan, Leyla Azarang, Jacco van Rheenen, E. Shelley Hwang, Yinyin Yuan, Grand Challenge PRECISION Consortium, Renee Menezes, Esther H. Lips, Jelle Wesseling
Format: Article
Language:English
Published: Nature Portfolio 2025-01-01
Series:npj Precision Oncology
Online Access:https://doi.org/10.1038/s41698-024-00769-6
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items